171 related articles for article (PubMed ID: 31996593)
1. Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?
Rial-Crestelo D; Sepúlveda MA; González-Gasca FJ; Geijo-Martínez P; Martínez-Alfaro E; Barberá JR; Yzusqui M; Casallo S; García M; Hornero CM; Espinosa-Gimeno A; Torralba M
AIDS; 2020 Mar; 34(3):427-432. PubMed ID: 31996593
[TBL] [Abstract][Full Text] [Related]
2. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
3. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
[TBL] [Abstract][Full Text] [Related]
4. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
5. [Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients].
Liao BL; Li LH; Zhong HL; Li H; Li YH; Chen SZ; Wen CY; Hu FY; Lan Y; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):776-780. PubMed ID: 34517460
[No Abstract] [Full Text] [Related]
6. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
[TBL] [Abstract][Full Text] [Related]
7. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
8. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
[TBL] [Abstract][Full Text] [Related]
9. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.
Kohla MAS; Fayoumi AE; Akl M; Abdelkareem M; Elsakhawy M; Waheed S; Abozeid M
Clin Exp Med; 2020 Feb; 20(1):143-148. PubMed ID: 31792631
[TBL] [Abstract][Full Text] [Related]
10. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
[No Abstract] [Full Text] [Related]
11. Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV/HCV co-infected patients.
Yunihastuti E; Wicaksana B; Wiraguna A; Hidayah AJ; Amelia F; Natali V; Widhani A; Sulaiman AS; Kurniawan J
BMC Infect Dis; 2020 May; 20(1):372. PubMed ID: 32450844
[TBL] [Abstract][Full Text] [Related]
12. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
[TBL] [Abstract][Full Text] [Related]
14. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
18. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
Fahmy DM; Shokeir M; El Zeiny SM; Jonas MM; Abdallah A
J Pediatr; 2021 Apr; 231():110-116. PubMed ID: 33347957
[TBL] [Abstract][Full Text] [Related]
19. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
[TBL] [Abstract][Full Text] [Related]
20. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]